research chemical raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-22. Anything still debated is marked as such rather than presented as settled.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or lower | Desiccated and protected from light |
| Common analytical method | LC-MS/MS | Detects parent drug and metabolites |
| Solubility class | Lipophilic; soluble in organic solvents | Low aqueous solubility |
| Molecular weight | 437.94 g/mol | Calculated from reported formula |
| Synonyms | SR9009; REV-ERB agonist | Code name used in scientific literature |
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Central nervous system: fatigue, dizziness, drowsiness, lightheadedness, confusion, nightmares, agitation, increased anxiety, difficulty sleeping, seizures (infrequently), temporary confusion (delirium), rarely induction of hypomania and psychosis, extrapyramidal side effects (rarely), abuse in patients with polytoxicomania (rarely), ringing in the ears (tinnitus) Anticholinergic: dry mouth, constipation, even ileus (rarely), difficulties in urinating, sweating, precipitation of glaucoma Antiadrenergic: Low blood pressure, (if patient arises too fast from the lying/sitting position to standing—known as orthostatic hypotension), abnormal heart rhythms (e.g., sinus tachycardia, bradycardia, and atrioventricular block) Allergic/toxic: skin rash, photosensitivity, liver damage of the cholestatic type (rarely), hepatitis (extremely rare), leuko- or thrombocytopenia (rarely), agranulocytosis (very rarely), hypoplastic anemia (rarely) Others: frequently increased appetite and weight gain, rarely nausea, rarely high blood pressure. May increase or decrease liver enzyme levels in the blood of some people. The side effects of low-dose doxepin for insomnia in long-term clinical trials (28 to 85 days) in adults and elderly people were as follows:
The measles vaccine is equally effective for preventing measles in all formulations, but side effects vary for different combinations. The World Health Organization (WHO) recommends measles vaccine be given at nine months of age in areas of the world where the disease is common, or at twelve months where the disease is not common. Measles vaccine is based on a live but weakened strain of measles. It comes as a dried powder that is mixed with a specific liquid before being injected either just under the skin or into a muscle. Verification that the vaccine was effective can be determined by blood tests. The measles vaccine was first introduced in 1963. In that year, the Edmonston-B strain of measles virus was turned into a vaccine by John Enders and colleagues and licensed in the United States. In 1968, an improved and even weaker measles vaccine was developed by Maurice Hilleman and colleagues, and began to be distributed, becoming the only measles vaccine used in the United States since 1968. About 86% of children globally had received at least one dose of the vaccine as of 2018. In 2021, at least 183 countries provided two doses in their routine immunization schedule. It is on the World Health Organization's List of Essential Medicines. As outbreaks easily occur in under-vaccinated populations, non-prevalence of disease is seen as a test of sufficient vaccination within a population.
== Physiological effects == Catecholamines cause general physiological changes that prepare the body for physical activity (the fight-or-flight response). Some typical effects are increases in heart rate, blood pressure, blood glucose levels, and a general reaction of the sympathetic nervous system. Some drugs, like tolcapone (a central COMT-inhibitor), raise the levels of all the catecholamines. Increased catecholamines may also cause an increased respiratory rate (tachypnoea) in patients. Catecholamine is secreted into urine after being broken down, and its secretion level can be measured for the diagnosis of illnesses associated with catecholamine levels in the body. Urine testing for catecholamine is used to detect pheochromocytoma.
The southern districts of Le Havre are mainly used for industrial and port activities. There are buildings in brick from the 19th century, large developments (Chicago, Les Neiges), worker estates, SMEs, warehouses, dock and port facilities, and transport infrastructure. The southern districts have for some years experienced profound change due to European funding. It is revitalizing areas neglected by industrial and port activities by developing tertiary activities. Thus, the docks have been completely transformed into sports and entertainment complexes (Dock Océane), a mall (Docks Vauban), and an exhibition hall (Docks Café). Les Bains Des Docks was designed by the architect Jean Nouvel. At the end of 2012 students from Sciences Po's Europe-Asia undergraduate college campus and from INSA integrated new buildings next to the ISEL (Higher Institute of logistics studies) and the future ENSM (Ecole Nationale Supérieure Maritime). The new medical axis around the new Clinic des Ormeaux was built in the neighbourhoods where many homes are planned with the aim of promoting social mix. The City of the Sea and of Sustainable Development (Odyssey 21) will be organized around a metal tower one hundred metres high designed by Jean Nouvel: the project was suspended in 2007 but the work should finally begin in 2013. The municipality has to attract some 300,000 visitors per year.
IL-10 shares similar immunomodulating mechanisms to TGF-β. It is thought that both cytokines reduce the rate of apoptosis in human alveolar macrophages, thus indirectly enhancing alveolar macrophage-mediated inhibition of T-cell proliferation. There is a significant increase in the basal rate of apoptosis upon activation by bacterial products. Apoptosis is particularly regulated by the presence of cytokines: IFNγ increases the rate of apoptosis, whereas IL-10 and TGF-β decrease it. However, IL-10 has counterproductive effects on the immune system, and has been shown to actually promote infection by foreign pathogens. The role of IL-10 in bacterial and parasitic infection has been discovered as a strategy to evade host immune systems. There are bacteria which parasitize AMs by invading through their membranes, and thrive by growing and replicating inside of them, exploiting AMs as host cells. Normally, this infection can be eliminated by T-cells, which activate enzymes in alveolar macrophages that destroy the bacteria; but these bacteria have been shown to alter the cytokine signaling network to their advantage. As an inhibitory cytokine, IL-10 facilitates the infection of human alveolar macrophages and monocytes by completely reversing the protective effect of IFNγ against intracellular Legionella pneumophila replication.
Sources: en.wikipedia.org
=== Specific activity === The specific activity of an enzyme is another common unit. This is the activity of an enzyme per milligram of total protein (expressed in μmol min−1 mg−1). Specific activity gives a measurement of enzyme purity in the mixture. It is the micro moles of product formed by an enzyme in a given amount of time (minutes) under given conditions per milligram of total proteins. Specific activity is equal to the rate of reaction multiplied by the volume of reaction divided by the mass of total protein. The SI unit is katal/kg, but a more practical unit is μmol/(mg*min). Specific activity is a measure of enzyme processivity (the capability of enzyme to be processed), at a specific (usually saturating) substrate concentration, and is usually constant for a pure enzyme. An active site titration process can be done for the elimination of errors arising from differences in cultivation batches and/or misfolded enzyme and similar issues. This is a measure of the amount of active enzyme, calculated by e.g. titrating the amount of active sites present by employing an irreversible inhibitor. The specific activity should then be expressed as μmol min−1 mg−1 active enzyme. If the molecular weight of the enzyme is known, the turnover number, or μmol product per second per μmol of active enzyme, can be calculated from the specific activity. The turnover number can be visualized as the number of times each enzyme molecule carries out its catalytic cycle per second.
This molecule is then reduced to mevalonate by the enzyme HMG-CoA reductase. Production of mevalonate is the rate-limiting and irreversible step in cholesterol synthesis and is the site of action for statins (a class of cholesterol-lowering drugs).
Tryptophan is an important intrinsic fluorescent probe (amino acid), which can be used to estimate the nature of the microenvironment around the tryptophan residue. Most of the intrinsic fluorescence emissions of a folded protein are due to excitation of tryptophan residues.
Following four months Transport was absorbed into the new "monster ministry" of the Department for the Environment, under Heseltine's ally Peter Walker. Heseltine was still responsible for transport, but also for local government reform, covered in the Local Government Act 1972. Redcliffe-Maude's proposals for unitary councils (i.e. merging the two layers of county and borough/district councils) were abandoned. Many historic counties were abolished. Large Metropolitan counties were created around the big cities, but many smaller cities lost their county borough status. One such was Plymouth, the eastern suburbs of which lay in Heseltine's seat of Tavistock. Plymouth opinion was particularly angry that education was now to be run by Devon County Council in Exeter, 40 miles away. Heseltine declined to support a campaign by Plymouth MP Dame Joan Vickers to create a Tamarside Metropolitan county, and was rebuked by Sir Henry Studholme, his predecessor as MP for Tavistock, for declining to support (on the grounds that as minister he might have to adjudicate any dispute) Plymouth Council's attempt to buy more land near Sparkwell to develop light industry under its control.
As an isolate - through the process of wet fractionation which produces a high protein concentration As a concentrate - through the process of dry fractionation which produces a low protein concentration In textured form, which is when it is used in food products as a substitute for other products, such as meat alternatives Pea protein has low allergenicity and high nutritional value. It is common as a source of protein in vegan and vegetarian food, and in protein supplement products.
Sources: en.wikipedia.org
According to Future Forward PAC, a derivative of his campaign's "Kamala is for they/them, President Trump is for you" attack ad (with commentary by Charlamagne tha God spliced in) was one of the most effective of the campaign, shifting the race 2.7 percentage points in favor of Trump after viewers watched it. However, findings from an RCT study released by Ground Media/GLAAD said that the ad did not have an impact on who viewers intended to vote for.
=== EC 1.17.4 With a disulfide as acceptor === EC 1.17.4.1: ribonucleoside-diphosphate reductase EC 1.17.4.2: ribonucleoside-triphosphate reductase (thioredoxin) EC 1.17.4.3: transferred to EC 1.17.7.1, (E)-4-hydroxy-3-methylbut-2-enyl-diphosphate synthase. EC 1.17.4.4: vitamin-K-epoxide reductase (warfarin-sensitive) EC 1.17.4.5: vitamin-K-epoxide reductase (warfarin-insensitive)
S: Skin. The skin of the scalp contains numerous hair follicles and sebaceous glands. C: Connective tissue. A dense subcutaneous layer of fat and fibrous tissue that lies beneath the skin, containing the nerves and vessels of the scalp. A: Aponeurosis. The epicranial aponeurosis or galea aponeurotica is a tough layer of dense fibrous tissue which anchors the above layers in place. It runs from the frontalis muscle anteriorly to the occipitalis posteriorly. L: Loose areolar connective tissue. This layer has a gel-like consistency, and allows the more superficial layers of the scalp to shift about in relation to the pericranium. It is constituted of more matrix than fibers. It contains random collagen I bundles, collagen III and is rich in glycosaminoglycans (GAGs). In craniofacial surgery and neurosurgery this layer provides an easy plane of separation between the upper three layers and the pericranium. In scalping the scalp is also torn off through this layer. The layer is sometimes referred to as the "danger zone" because infectious agents can easily spread through it to emissary veins which drain into the cranium. P: Pericranium. This is the periosteum of the skull bones, a membrane that provides nutrition to the bone and the capacity for repair. During surgery it can be lifted from the bone to allow the removal of windows of bone (craniotomy).
Tramadol can have pharmacodynamic, pharmacokinetic, and pharmacogenetic interactions. Tramadol is metabolized by CYP2D6 enzymes which contributes to the metabolism of approximately 25% of all medications. Any medications with the ability to inhibit or induce these enzymes may interact with tramadol. These include common antiarrhythmics, antiemetics, antidepressants (sertraline, paroxetine, and fluoxetine in particular), antipsychotics, analgesics, and tamoxifen.- Due to tramadol's serotonergic effects, tramadol has the potential to contribute to the development of an acute or chronic hyper-serotonin state called serotonin syndrome when used concurrently with other pro-serotonergic medications such as antidepressants (SSRIs, SNRIs, tricyclics, MAOIs), antipsychotics, triptans, cold medications containing dextromethorphan, and some herbal products such as St. John's wort. Concurrent use of 5-HT3 antagonists such as ondansetron, dolasetron, and palonosetron may reduce the effectiveness of both drugs. Tramadol also acts as an opioid agonist and thus can increase the risk for side effects when used with other opioid and opioid-containing analgesics (such as morphine, pethidine, tapentadol, oxycodone, fentanyl, and Tylenol 3). Tramadol increases the risk for seizures by lowering the seizure threshold. Using other medications that lower seizure threshold – such as antipsychotic medications, bupropion (an anti-depressant and smoking cessation drug), and amphetamines – can further increase this risk.
Dinosaurs diverged from their archosaur ancestors during the Middle to Late Triassic epochs, roughly 20 million years after the devastating Permian–Triassic extinction event wiped out an estimated 96% of all marine species and 70% of terrestrial vertebrate species approximately 252 million years ago. The oldest dinosaur fossils known from substantial remains date to the Carnian epoch of the Triassic period and have been found primarily in the Ischigualasto and Santa Maria Formations of Argentina and Brazil, and the Pebbly Arkose Formation of Zimbabwe. The Ischigualasto Formation (radiometrically dated at 231–230 million years old) has produced the early saurischian Eoraptor, originally considered a member of the Herrerasauridae but now considered to be an early sauropodomorph, along with the herrerasaurids Herrerasaurus and Sanjuansaurus, and the sauropodomorphs Chromogisaurus, Eodromaeus, and Panphagia. Eoraptor's likely resemblance to the common ancestor of all dinosaurs suggests that the first dinosaurs would have been small, bipedal predators. The Santa Maria Formation (radiometrically dated to be older, at 233.23 million years old) has produced the herrerasaurids Gnathovorax and Staurikosaurus, along with the sauropodomorphs Bagualosaurus, Buriolestes, Guaibasaurus, Macrocollum, Nhandumirim, Pampadromaeus, Saturnalia, and Unaysaurus. The Pebbly Arkose Formation, which is of uncertain age but was likely comparable to the other two, has produced the sauropodomorph Mbiresaurus, along with an unnamed herrerasaurid.
Sources: en.wikipedia.org
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.
Research samples are typically kept frozen, desiccated, and protected from light. Stock solutions are often aliquoted to reduce freeze-thaw cycles.
High-performance liquid chromatography and nuclear magnetic resonance are standard for purity and identity. Mass spectrometry confirms molecular weight.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.